CAREDX, INC. vs VERACYTE, INC., two Medical Diagnostics stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CDNA and VCYT diverge most: on operating margin, CDNA reads 85.8% and VCYT reads 15.3%; on return on invested capital, CDNA reads 24.6% and VCYT reads 7.3%. The rest of the comparable metrics sit closer together. What VCYT's price implies is a somewhat stretched bet versus history (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | CDNA | VCYT |
|---|---|---|
| Price | $43.64 | $46.13 |
| Market cap | $2.3B | $3.7B |
| Sector | Medical Diagnostics | Medical Diagnostics |
| Stage | Growth | Growth |
| P/E | 21.1 | 33.0 |
| P/B | 5.30 | 2.67 |
| P/S | 4.93 | 6.60 |
| EV/EBITDA | 16.8 | 30.7 |
| Revenue growth | +34.3% | +17.3% |
| Gross margin | — | 72.2% |
| Operating margin | 85.8% | 15.3% |
| Net margin | 24.2% | 20.4% |
| Return on equity | 26.1% | 8.3% |
| Return on assets | 20.8% | 7.7% |
| Return on invested capital | 24.6% | 7.3% |
| FCF yield | 3.9% | 4.5% |
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 4.58 | 9.16 |
| Altman Z (solvency) | 6.99 | 6.54 |
| Piotroski F (quality) | 5 / 9 | 6 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.